ICON plc employs a range of advanced technologies to enhance clinical development, particularly in the fields of oncology and obesity treatment. The company focuses on integrating Clinical Outcome Assessments (COAs) with Digital Health Technologies (DHTs) to provide a comprehensive view of treatment impacts. COAs, which capture patient-reported outcomes, are complemented by DHTs that gather objective health data through wearables and mobile applications. This combination allows for a more nuanced understanding of how treatments affect patients' quality of life and health metrics, ultimately improving the likelihood of regulatory approval and patient outcomes.

Additionally, ICON leverages artificial intelligence (AI) to optimize various aspects of clinical trials, including site identification and risk management for post-marketing requirements. Their technology solutions also encompass advanced data management systems and operational infrastructures that facilitate efficient clinical trial management. By utilizing these technologies, ICON aims to streamline processes, enhance patient recruitment, and ensure robust data collection, thereby addressing the complexities of modern drug development and improving the overall efficiency of clinical research.

United States

ICON works to accelerate the development of live-saving drugs and devices by providing a wide range of consulting, development, and commercialization services.

ICON plc

Company Details